How do I risk‑stratify a patient with pulmonary embolism using the PESI (Pulmonary Embolism Severity Index) and simplified sPESI scores?

Risk Stratification of Pulmonary Embolism Using PESI and sPESI

Use the simplified PESI (sPESI) as your primary risk stratification tool for pulmonary embolism—it reliably identifies low-risk patients (sPESI = 0) who have <1-3% 30-day mortality and are candidates for early discharge or outpatient management. 1

Understanding the Scoring Systems

Original PESI

The original PESI incorporates 11 variables with different point values 1:

• Age (actual years as points)
• Male sex (+10 points)
• Cancer (+30 points)
• Chronic heart failure (+10 points)
• Chronic pulmonary disease (+10 points)
• Pulse ≥110 bpm (+20 points)
• Systolic BP <100 mmHg (+30 points)
• Respiratory rate ≥30 breaths/min (+20 points)
• Temperature <36°C (+20 points)
• Altered mental status (+60 points)
• Oxygen saturation <90% (+20 points)

The original PESI classifies patients into five risk classes (I-V), with classes I-II considered low-risk 1. While it has greater discriminatory power than sPESI (AUC 0.78 vs 0.72), it classifies more patients as low-risk (40.9% vs 36.8%) 2.

Simplified PESI (sPESI)

The sPESI uses only 6 variables, each worth 1 point 1, 3:

• Age >80 years
• Cancer
• Chronic cardiopulmonary disease
• Heart rate ≥110 bpm
• Systolic BP <100 mmHg
• Oxygen saturation <90%

A score of 0 = low-risk; score ≥1 = high-risk 3, 4

Clinical Application Algorithm

Step 1: Calculate sPESI Score

Assess the 6 variables above and assign 1 point for each present 1.

Step 2: Risk Classification

• sPESI = 0 (Low-Risk): 30-day mortality 1.0-2.7%, recurrent VTE 1.3%, major bleeding 1.1% 5, 4, 6
• sPESI ≥1 (High-Risk): 30-day mortality 8.1-10.9%, recurrent VTE 2.8%, major bleeding 4.0% 5, 4

Step 3: Management Implications

For sPESI = 0 patients 1, 4:

• Consider early hospital discharge or home treatment
• These patients have been prospectively validated for outpatient management
• 30-day adverse event rates are acceptably low across mortality, recurrent VTE, and bleeding outcomes

For sPESI ≥1 patients 1:

• Requires further risk stratification into intermediate-low vs intermediate-high risk
• Assess for RV dysfunction (echocardiogram or CTPA) and cardiac biomarkers (troponin, NT-proBNP)
• Intermediate-high risk defined as: positive imaging for RV dysfunction AND positive cardiac biomarkers
• Intermediate-low risk: positive imaging OR biomarkers (or neither)

Key Strengths and Limitations

Why sPESI is Preferred in Practice

• Simplicity: Only 6 equally-weighted variables vs 11 differently-weighted variables 1, 3
• Excellent negative predictive value: 97-98% for identifying patients who will NOT die 2
• High sensitivity: 89% for detecting patients at risk of death 2
• Validated across multiple populations: European, American, and Asian cohorts 3, 4, 6
• Good inter-rater reliability: Kappa = 0.69 7

Important Caveats

The sPESI has a 4.7-fold increased risk of 30-day mortality when ≥1 point is present 6. However, the original PESI does have slightly better discriminatory power and identifies a larger proportion of patients as low-risk 2. In real-world practice, the ease of use and speed of calculation make sPESI the preferred tool, particularly in busy emergency departments 1, 6.

Common Pitfalls to Avoid

• Do not use sPESI alone for intermediate-risk patients: Those with sPESI ≥1 require additional assessment with imaging and biomarkers to guide advanced therapy decisions 1
• Do not ignore concomitant DVT: Presence of DVT increases 30-day mortality (OR 1.9) and indicates significant comorbidity 1
• sPESI is for hemodynamically stable patients only: High-risk PE (hemodynamic instability/shock) requires immediate intervention regardless of score 1, 8
• Consider baseline comorbidities: Patients with sPESI = 0 have significantly lower Charlson Comorbidity Index scores (1.0 vs 3.4) 5

Integration with ESC Risk Classification

The 2019 ESC Guidelines integrate sPESI/PESI into a comprehensive risk assessment strategy 1:

• High-risk PE: Hemodynamic instability (requires emergency reperfusion)
• Intermediate-high risk: sPESI ≥1 + RV dysfunction + positive biomarkers
• Intermediate-low risk: sPESI ≥1 + one or no positive markers
• Low-risk PE: sPESI = 0 (assessment of RV/biomarkers optional)

This stratification directly guides therapeutic decisions, with only intermediate-high risk patients potentially benefiting from advanced therapies beyond anticoagulation alone 1.